Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk reports up to 19.7% mean weight loss in Phase 2 trial of triple agonist UBT251, expanding its next-generation obesity pipeline.
Novo Nordisk announced Monday it plans to invest 8.5 billion Danish kroner (€1.14B) to establish a completely new production facility in Odense, Denmark.
Novo Nordisk has said plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Nordisk’s NovoSeven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding.
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s a 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes.
Novo Nordisk has expanded its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use…
Novo Nordisk’a new results from the STEP phase 3a clinical trial programme showed weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
The U.S. Food and Drug Administration approved on Friday Novo Nordisk’s Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.
Novo Nordisk’s operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019 with reported sales within Diabetes and obesity increased by 10% to DKK 50.1 billion (6% at CER), driven by Diabetes growing 4% at CER and Obesity growing 56% at CER. Sales within Biopharmaceuticals increased by 7% to DKK 9.3 billion (3% at CER).